History of depression and smoking cessation outcome: a meta-analysis.

  title={History of depression and smoking cessation outcome: a meta-analysis.},
  author={Brian Hitsman and Belinda Borrelli and Dennis E. McChargue and Bonnie J. Spring and Raymond S. Niaura},
  journal={Journal of consulting and clinical psychology},
  volume={71 4},
The authors conducted a meta-analysis of published studies to (a) evaluate the premise that a history of major depression is associated with failure to quit smoking and (b) identify factors that moderate the relationship between history of depression and cessation outcome. Fifteen studies met the selection requirements and were coded for various study methodology and treatment characteristics. DSTAT was used to calculate individual study effect sizes, determine the mean effect size across… 

Past major depression and smoking cessation outcome: a systematic review and meta-analysis update.

An increased focus on the identification of effective treatments or treatment adaptations that eliminate this disparity in smoking cessation for MD+ smokers is needed.

Relationship of Depression to Smoking Outcomes in a Methadone-Maintained Population

Depressive symptoms have little influence on smoking cessation outcomes in this population of methadone-maintained smokers but depression was not associated significantly with motivation to quit smoking at baseline, time to first cigarette, or any behavioral indicator of smoking during the follow-up period.

Fluoxetine, smoking, and history of major depression: A randomized controlled trial.

Fluoxetine initially enhanced cessation for H+ smokers but subsequently impaired cessation regardless of depressive history, and six months after quit date, fluoxettine-treated participants were 3.3 times more likely to be smoking.

The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion.

Depressive symptoms at baseline were not predictive of cessation; however, increases in depressive symptoms from baseline predicted reduced cessation at the end of treatment, and higher depressive symptoms at week 6 and month 6 were associated with a reduced likelihood of smoking cessation at those time points.

Depression predicts smoking early but not late in a quit attempt.

Depression history showed that depression history was a powerful predictor of smoking early in the quit attempt, and smoking during the first week was not predictive of smoking at 6 months in those with a history of depression but was predictive among those with nohistory of depression.

Two decades of smoking cessation treatment research on smokers with depression: 1990-2010.

Little information exists to inform a treatment approach for smokers with Current Major Depressive Disorder, Dysthymia, and Minor Depression and few studies report gender and racial differences in the relationship of depression and smoking cessation outcomes, thus suggesting major areas for targeted research.

Effects of anhedonia on days to relapse among smokers with a history of depression: a brief report.

Investigation of the relation between anhedonia and relapse latency among MDD history smokers following a brief smoking cessation workshop suggests thatAnhedonia may constitute a proximal risk factor identifying depressive history smokers more likely to relapse to smoking.

Depression motivates quit attempts but predicts relapse: differential findings for gender from the International Tobacco Control Study.

Smokers with depressive symptoms or diagnosis make more quit attempts than their non-depressed counterparts, which may be explained by higher motivation to quit, but they are also more likely to relapse in the first month.

Predictors of sustained smoking cessation: a prospective analysis of chronic smokers from the alpha-tocopherol Beta-carotene cancer prevention study.

Compared with sustained quitters, relapsers were more likely to report symptoms of emotional distress and higher levels of nicotine dependence, to drink more alcohol, and to report more medical conditions.



Smoking cessation and the course of major depression: a follow-up study

Depression and depressive symptoms in smoking cessation.

Smoking Cessation in Individuals with Depression

The efficacy, suitability and other treatment issues involved in using nicotine replacement therapy, antidepressant treatment and cognitive-behavioural interventions to help depressed smokers quit smoking are discussed.

Major depression and stages of smoking. A longitudinal investigation.

The observed influences from major depression to subsequent daily smoking and smoking to major depression support the plausibility of shared etiologies.

Symptoms of depression and survival experience among three samples of smokers trying to quit.

Results were robust and uniformly clear, indicating that low levels of depressive symptoms assessed at baseline predict time to 1st cigarette smoked after attempted quitting.

Comorbidity, Smoking Behavior and Treatment Outcome

High prevalence rates of lifetime psychiatric illness and substance use disorders are reported for chronic smokers, and subsyndromal psychiatric symptoms may play a role in smoking behavior in combination with diagnosable disorders.

Development of major depressive disorder during smoking-cessation treatment.

It is suggested that a subset of smokers may be at risk for developing major depressive disorder after smoking cessation, and those who developed MDD after treatment scored significantly higher on measures of depressed mood at baseline than those who did not developMDD after smoking-cessation treatment.

Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking.

Nortriptyline is a promising adjunct for smoking cessation and increases in negative affect after quitting smoking are attenuated by nortripty Line, independent of depression history.

Measures of abstinence in clinical trials: issues and recommendations.

A workgroup formed by the Society for Research on Nicotine and Tobacco reviewed the literature on abstinence measures used in trials of smoking cessation interventions. We recommend that trials

Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo-controlled study.

No treatment differences were found in trends over time for measures of mood, withdrawal symptoms, pleasant activities and events, self-efficacy, and optimism and pessimism.